{"id":"placebo-of-tacrolimus-ointment","safety":{"commonSideEffects":[{"rate":"null","effect":"Skin burning sensation"},{"rate":"null","effect":"Skin irritation"},{"rate":"null","effect":"Pruritus"}]},"_chembl":{"chemblId":"CHEMBL3989887","moleculeType":"Small molecule","molecularWeight":"822.05"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting calcineurin, tacrolimus ointment reduces the production of interleukin-2, a cytokine involved in the activation and proliferation of T-cells. This results in a decrease in the immune response, which is beneficial for preventing organ rejection in transplant patients.","oneSentence":"Tacrolimus ointment is an immunosuppressant that works by inhibiting calcineurin, a protein necessary for T-cell activation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:14.754Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ rejection in transplant patients"}]},"trialDetails":[{"nctId":"NCT06306274","phase":"PHASE2, PHASE3","title":"Topical Tacrolimus for Breast Cancer-related Lymphedema","status":"ENROLLING_BY_INVITATION","sponsor":"Odense University Hospital","startDate":"2024-09-09","conditions":"Lymphedema","enrollment":80},{"nctId":"NCT05577637","phase":"PHASE1","title":"Comparitive Study Between Uvb Alone and Uvb With Topical Tacrolimus 0.03% for the Treatment of Vitiligo","status":"COMPLETED","sponsor":"Combined Military Hospital Abbottabad","startDate":"2021-05-01","conditions":"Vitiligo","enrollment":60},{"nctId":"NCT05032248","phase":"NA","title":"Uses of Tacrolimus in Behcet Disease","status":"COMPLETED","sponsor":"Assiut University","startDate":"2019-04-01","conditions":"Oral Ulcer, Behcet Syndrome","enrollment":40},{"nctId":"NCT04114097","phase":"PHASE4","title":"The Effects of Topical Corticosteroid Use on Insulin Sensitivity and Bone Turnover","status":"COMPLETED","sponsor":"Jacob Thyssen","startDate":"2019-08-22","conditions":"Atopic Dermatitis, Atopic Eczema","enrollment":36},{"nctId":"NCT02466997","phase":"PHASE3","title":"Efficacy of Tacrolimus in Adults With Facial Non-segmental Vitiligo - VITAC","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2016-02-23","conditions":"Vitiligo","enrollment":42},{"nctId":"NCT03152019","phase":"PHASE2","title":"Efficacy and Safety of a 0.1% Tacrolimus Nasal Ointment as a Treatment for Epistaxis in Hemorrhagic Hereditary Telangiectasia (HHT)","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2017-05-22","conditions":"Hemorrhagic Hereditary Telangiectasia (HHT)","enrollment":50},{"nctId":"NCT02601703","phase":"PHASE3","title":"To Study Generic Tacrolimus Ointment, 0.1% in the Treatment of Moderate to Severe Atopic Dermatitis (Inflammation of Skin: Itchy, Red, Swollen, and Cracked Skin)","status":"COMPLETED","sponsor":"Glenmark Pharmaceuticals Ltd. India","startDate":"2015-08","conditions":"Atopic Dermatitis","enrollment":1110},{"nctId":"NCT01418131","phase":"PHASE4","title":"Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis","status":"COMPLETED","sponsor":"The University of Western Australia","startDate":"2012-10","conditions":"Ulcerative Colitis","enrollment":21},{"nctId":"NCT01544842","phase":"NA","title":"Tacrolimus Ointment in Oral Lichen Planus","status":"TERMINATED","sponsor":"University of Oulu","startDate":"2004-08","conditions":"Oral Lichen Planus","enrollment":28},{"nctId":"NCT01139450","phase":"PHASE3","title":"Study of 0417 Ointment in the Treatment of Atopic Dermatitis","status":"COMPLETED","sponsor":"Fougera Pharmaceuticals Inc.","startDate":"2008-01","conditions":"Atopic Dermatitis","enrollment":899},{"nctId":"NCT01053247","phase":"PHASE3","title":"Study of 0416 Ointment in the Treatment of Atopic Dermatitis","status":"COMPLETED","sponsor":"Fougera Pharmaceuticals Inc.","startDate":"2008-01","conditions":"Atopic Dermatitis","enrollment":793},{"nctId":"NCT00480896","phase":"PHASE3","title":"Treatment and Control of Atopic Dermatitis With 0.03% Tacrolimus Ointment","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2004-06","conditions":"Dermatitis, Atopic","enrollment":250},{"nctId":"NCT00667056","phase":"PHASE4","title":"Study of the Safety and Efficacy of Tacrolimus Ointment in Treating Chronic Allergic Contact Dermatitis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2004-07","conditions":"Dermatitis","enrollment":98},{"nctId":"NCT00480610","phase":"PHASE3","title":"Treatment and Control of Atopic Dermatitis With 0.1% Tacrolimus Ointment","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2004-04","conditions":"Dermatitis, Atopic","enrollment":226},{"nctId":"NCT00106496","phase":"PHASE4","title":"A Multi-Center Study of Short and Long-term Use of Protopic Ointment in Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2004-10","conditions":"Dermatitis, Atopic","enrollment":410},{"nctId":"NCT01841008","phase":"PHASE2, PHASE3","title":"Maintenance Treatment of Non Segmental Vitiligo With Tacrolimus Ointment 0.1% Versus Control","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2011-12","conditions":"Pigmentation Disorders, Vitiligo","enrollment":35},{"nctId":"NCT00535691","phase":"PHASE2","title":"Tacrolimus Ointment Pharmacokinetics in Infants With Atopic Dermatitis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2003-04","conditions":"Dermatitis, Atopic","enrollment":53},{"nctId":"NCT00833079","phase":"PHASE1","title":"Bioequivalence of Two Tacrolimus 0.1% Topical Ointment Formulations in Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2008-10","conditions":"Atopic Dermatitis","enrollment":500},{"nctId":"NCT01702181","phase":"PHASE1","title":"A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2012-08","conditions":"Atopic Dermatitis","enrollment":92},{"nctId":"NCT01388517","phase":"PHASE4","title":"Clinical Trial of 0.0003% Calcitriol, 0.1% Tacrolimus, and Petrolatum for the Treatment of Pityriasis Alba","status":"COMPLETED","sponsor":"Universidad Autonoma de San Luis Potosí","startDate":"2008-01","conditions":"Pityriasis Alba","enrollment":39},{"nctId":"NCT01320579","phase":"PHASE2","title":"Investigation of the Efficacy of 2.5% and 5% Cis-urocanic Acid in Patients With Moderate or Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"BioCis Pharma Ltd","startDate":"2011-03","conditions":"Atopic Dermatitis","enrollment":159},{"nctId":"NCT01068054","phase":"PHASE2, PHASE3","title":"Efficacy Study of FK-506 and Cyclosporine in Vernal Keratoconjunctivits (VKC)","status":"COMPLETED","sponsor":"Siriraj Hospital","startDate":"2003-06","conditions":"Keratoconjunctivitis, Vernal","enrollment":24},{"nctId":"NCT00807690","phase":"PHASE3","title":"Vitiligo Treated With TL01 Combined With Tacrolimus Ointment Versus Placebo","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2005-11","conditions":"Vitiligo","enrollment":""},{"nctId":"NCT00134394","phase":"PHASE2","title":"Etanercept With Tacrolimus for Psoriasis","status":"COMPLETED","sponsor":"University of Medicine and Dentistry of New Jersey","startDate":"2005-02","conditions":"Psoriasis","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":31,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo of Tacrolimus Ointment","genericName":"Placebo of Tacrolimus Ointment","companyName":"Glenmark Pharmaceuticals Ltd. India","companyId":"glenmark-pharmaceuticals-ltd-india","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tacrolimus ointment is an immunosuppressant that works by inhibiting calcineurin, a protein necessary for T-cell activation. Used for Prevention of organ rejection in transplant patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}